UNICA IRIS Institutional Research Information System

MARONGIU, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 152.328
NA - Nord America 14.045
AS - Asia 5.355
SA - Sud America 958
Continente sconosciuto - Info sul continente non disponibili 570
AF - Africa 214
OC - Oceania 65
Totale 173.535
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 145.274
US - Stati Uniti d'America 13.686
NL - Olanda 3.820
SG - Singapore 2.005
CN - Cina 1.633
BR - Brasile 708
UA - Ucraina 679
SE - Svezia 677
VN - Vietnam 507
DE - Germania 422
GB - Regno Unito 367
FI - Finlandia 338
FR - Francia 261
HK - Hong Kong 226
CA - Canada 196
BD - Bangladesh 155
IN - India 149
KR - Corea 91
AR - Argentina 76
RU - Federazione Russa 74
MX - Messico 71
IQ - Iraq 70
ZA - Sudafrica 64
JP - Giappone 59
TR - Turchia 59
ES - Italia 55
AU - Australia 54
PK - Pakistan 51
AT - Austria 46
ID - Indonesia 44
PL - Polonia 43
CO - Colombia 41
IE - Irlanda 40
EC - Ecuador 39
IR - Iran 37
EG - Egitto 32
BE - Belgio 31
MA - Marocco 29
MY - Malesia 28
PH - Filippine 28
IL - Israele 27
SA - Arabia Saudita 27
RO - Romania 25
CL - Cile 23
VE - Venezuela 23
UZ - Uzbekistan 22
CH - Svizzera 21
TN - Tunisia 19
KE - Kenya 18
PE - Perù 18
TW - Taiwan 18
HU - Ungheria 17
JO - Giordania 17
LT - Lituania 17
JM - Giamaica 16
CR - Costa Rica 15
DK - Danimarca 15
ET - Etiopia 15
CZ - Repubblica Ceca 14
PY - Paraguay 14
AE - Emirati Arabi Uniti 13
AL - Albania 13
TH - Thailandia 13
BG - Bulgaria 11
NZ - Nuova Zelanda 11
RS - Serbia 11
KZ - Kazakistan 10
NP - Nepal 10
PR - Porto Rico 10
BA - Bosnia-Erzegovina 9
SV - El Salvador 9
AZ - Azerbaigian 8
DZ - Algeria 8
NI - Nicaragua 8
SD - Sudan 8
GR - Grecia 7
PT - Portogallo 7
UY - Uruguay 7
BH - Bahrain 6
GT - Guatemala 6
LB - Libano 6
SC - Seychelles 6
TT - Trinidad e Tobago 6
CY - Cipro 5
GE - Georgia 5
MK - Macedonia 5
NO - Norvegia 5
BO - Bolivia 4
BY - Bielorussia 4
CW - ???statistics.table.value.countryCode.CW??? 4
EE - Estonia 4
HR - Croazia 4
MT - Malta 4
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
GY - Guiana 3
HN - Honduras 3
KW - Kuwait 3
LU - Lussemburgo 3
MU - Mauritius 3
Totale 172.914
Salva come PNG Salva come JPEG
Città #
Cagliari 140.931
Amsterdam 3.746
Uta 3.412
Ashburn 1.541
Fairfield 1.365
Singapore 920
Woodbridge 838
San Jose 755
Dallas 658
Houston 656
Chandler 641
Seattle 557
Wilmington 528
Boardman 516
Ann Arbor 463
Cambridge 453
Nyköping 437
Jacksonville 351
Council Bluffs 313
Beijing 312
Los Angeles 245
Helsinki 204
Hong Kong 200
The Dalles 177
New York 170
Santa Clara 161
Dearborn 159
Ho Chi Minh City 154
Lauterbourg 145
Boston 130
Shanghai 118
Nanjing 112
Hanoi 99
Buffalo 96
Milan 94
Hefei 88
San Diego 87
Toronto 77
Seoul 73
São Paulo 73
Rome 65
Chicago 57
Dong Ket 56
Guangzhou 56
Hebei 55
Munich 52
London 50
Shenyang 49
Frankfurt am Main 46
Redwood City 46
Phoenix 43
Redondo Beach 41
Changsha 37
Orem 37
Nanchang 36
Tianjin 36
Denver 35
Nuremberg 35
Brooklyn 34
Jiaxing 34
Atlanta 33
Verona 31
Tokyo 30
Vienna 30
Baghdad 29
Columbus 29
Dublin 28
Brussels 27
Mexico City 27
Rio de Janeiro 27
Warsaw 27
Johannesburg 26
Orange 23
Brandenburg 22
Millbury 22
Montreal 22
San Francisco 22
Chennai 21
Da Nang 21
Lahore 21
Norwalk 21
Jinan 20
Manchester 20
Stockholm 20
Tashkent 20
Haiphong 19
Sassari 18
Bogotá 17
Las Vegas 17
Mountain View 17
North Bergen 17
Sydney 17
Turku 17
Ankara 16
Cape Town 16
Nairobi 16
Naples 16
Redmond 16
Zhengzhou 16
Dhaka 15
Totale 163.824
Salva come PNG Salva come JPEG
Nome #
Vaping effects on asthma: results from a web survey and clinical investigation 2.999
Sampling variability in hepatic iron concentration in beta-thalassemia 2.881
Heterogeneity of Antiphospholipid Syndrome (APS) as Characterized by Brain Perfusion Techniques. Towards New Ways of Syndrome Characterization 2.829
The venous thromboembolic risk and the clot wave analysis: a useful relationship? 2.790
Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review 2.770
Acquired factor VIII inhibitor and subsequent development of non-Hodgkin's lymphoma: a case report and review of the literature 2.594
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. 2.589
Olanzapine-associated portal and superior mesenteric vein thrombosis 2.529
Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis? 2.454
alpha 2 Antiplasmin and disseminated intravascular coagulation in liver cirrhosis 2.402
Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home 2.327
Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena 2.310
A retrospective cohort study of patients with pulmonary embolism: The impact of comorbidities on patient's outcome 2.200
Empathy and the Educational Approach to Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants 2.199
Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al 2.181
Management of Patients Taking Oral Anticoagulants Who Need Urgent Surgery for Hip Fracture 2.170
Pulmonary Thrombosis: A Clinical Pathological Entity Distinct from Pulmonary Embolism? 2.089
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience 2.053
Clot Waveform Analysis: From Hypercoagulability to Hypocoagulability - A Review 2.046
A Sardinian Family with Factor XI Deficiency 2.007
Ultrastructural findings of lung injury due to Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) following COVID-19 vaccination: a scanning electron microscopic study 2.001
Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: A report of an autoptic case and review of the literature 1.932
A “Catastrophic” Heparin-Induced Thrombocytopenia 1.901
Fibrinogen and D-dimer levels in autoimmune subclinical and overt hypothyroidism and effects of levothyroxine treatment. 1.844
The hemostatic system. 1st Part 1.831
Points of Care Testing International Normalized Ratio: Are They Useful for Monitoring Vitamin K Antagonists in a Thrombosis Center? 1.818
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1.779
Epidemiology of infection with HIV-1 in Sardinia: a multicentre prospective study 1.722
Point-of-care testing INR: an overview 1.690
Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No 1.672
Uneven hepatic iron and phosphorus distribution in b-thalassemia 1.667
Pulmonary thrombosis in 2019-nCoV pneumonia? 1.664
Risk of reoperation in bioprosthetic valve patients with indication for longterm anticoagulation. Results from the observational retrospective multicentre PLECTRUM study 1.655
Optimizing tailored DIEP flap insetting in unilateral immediate free autologous breast reconstruction 1.653
Immunological aspects in anti-HIV seronegative drug addicts. Correlation with the duration of heroin addiction and other viral infections 1.594
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study 1.591
Direct oral anticoagulants: what can we learn? 1.578
Comparison of prothrombin time INR and clot waveform analysis performed with 129-mmol/L and 105-mmol/L citrate tubes 1.567
Fatal Cytopenia Induced by Low-Dose Methotrexate in Elderly With Rheumatoid Arthritis. Identification of Risk Factors 1.519
T lymphocyte subsets and viral infections in Sardinian parenteral drug abusers: relationship to HIV infection 1.508
The criteria of the Italian Federation of Thrombosis Centres on DOACs: a ‘‘real world’’ application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist 1.495
Allele 4G of gene PAI-I associated with prothrombin mutation G20210A increases the risk for venous thrombosis 1.490
Thrombosis centres and AVKs monitoring in COVID-19 pandemic 1.459
Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients on oral anticoagulants 1.396
[Immunological aspects in anti-HIV seronegative drug addicts. Correlation with the duration of heroin addiction and other viral infections]. FT Aspetti immunologici nei tossicodipendenti anti-HIV sieronegativi. Correlazione con la durata di assunzione dell'eroina e con altre infezioni virali. 1.391
Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease? 1.374
Direct inhibitors of thrombin and factor Xa: the importance of laboratory skills 1.360
Hyperhomocysteinemia: could the post-methionine oral loading test sometimes be avoided? 1.342
A guide to oral anticoagulation 1.341
Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA(2)DS(2)VASc 1 or 2): a treatment dilemma 1.295
The Italian START-Register on anticoagulation with focus on atrial fibrillation 1.274
Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-Antagonists 1.263
Heparins and 2019-nCoV infection: a narrative review 1.262
A ‘‘two-step’’ educational approach for patients taking oral anticoagulants does not improve therapy control 1.244
Thyroid disorders and hypocoagulability 1.213
The predictive ability of bleeding risk stratification models in very old patients on vitaminK antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 1.188
Aspetti immunologici nei tossicodipendenti anti-HIV sieronegativi. Correlazione con la durata di assunzione dell’eroina e con altre infezioni virali 1.179
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome 1.165
High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice 1.149
Vitamin K antagonists (coumarins), drugs used in the prevention and treatment of cardioembolism, deep vein thrombosis, and pulmonary embolism 1.137
Fetal programming of atherosclerosis: may the barker hypothesis explain the susceptibility of a subset of patients to develop stroke or cardiac infarct? 1.115
Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago 1.094
Rheumatoid arthritis and thrombosis 1.088
A routine silica-based activated partial thromboplastin time (Hemosil aPTT-SP (TM)) mostly excludes the presence of lupus anticoagulant 1.087
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA) 1.080
Fetal programming of COVID-19: May the barker hypothesis explain the susceptibility of a subset of young adults to develop severe disease? 1.033
Infectious agents including COVID-19 and the involvement of blood coagulation and fibrinolysis. A narrative review 1.030
Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful? 1.022
Plasma prekallikrein (Fletcher factor) in hepatic cirrhosis 1.022
Clot characterization by multidisciplinary approach: biochemical and imaging parameters in a hypocoagulative setting. A pilot study 1.020
Hemarthrosis as acute presentation of acquired hemophilia in a patient with systemic lupus erythematosus: successful treatment and long-lasting remission 1.007
[Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy]. FT Effetto a breve termine della terapia con DL-carnitina per os ed L-carnitina e.v. nei pazienti uremici cronici in trattamento emodialitico. 994
Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy 959
Thrombotic sinusoiditis and local diffuse intrasinusoidal coagulation in the liver of subjects affected by COVID-19: The evidence from histology and scanning electron microscopy 939
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal 930
Center-related determinants of VKA anticoagulation quality: A prospective, multicenter evaluation 922
Aortic vulnerability to COVID-19: Is the microvasculature of vasa vasorum a key factor? A case report and a review of the literature 915
Scanning electron microscopy of lung disease due to COVID-19 – a case report and a review of the literature 863
Amoxicillina-acido clavulanico ed anticoagulanti orali:un’associazione potenzialmente pericolosa 854
Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk 854
Chronic spontaneous urticaria: a low-grade disseminated intravascular coagulation only partially reversed by Omalizumab 845
Bleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiency 842
Thromboembolic disease in patients with rheumatoid arthritis undergoing joint arthroplasty: Update on prophylaxes 841
null 824
Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants 802
Start-register (Survey on anticoagulated patients register): the first year of activity 800
null 772
Management of special conditions in patients on vitamin K antagonists 751
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 742
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study 708
Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation 704
null 679
Special indications for vitamin K antagonists: a review 679
null 644
Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) 642
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 640
null 633
Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2(V617F) mutation 622
null 617
null 616
Totale 142.853
Salva come PNG Salva come JPEG
Categoria #
all - tutte 249.374
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 249.374
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20226.447 0 0 0 0 750 715 606 496 695 941 1.137 1.107
2022/202313.972 1.309 1.837 1.693 1.231 1.226 1.483 702 1.112 912 789 1.042 636
2023/202416.064 668 938 777 1.394 1.606 2.190 2.415 1.091 774 1.176 1.605 1.430
2024/202528.643 6.075 7.319 3.400 2.925 3.247 1.828 2.115 175 429 432 291 407
2025/202613.770 551 369 1.237 1.019 719 609 1.735 592 4.482 1.254 720 483
2026/20272.717 216 455 739 1.235 72 0 0 0 0 0 0 0
Totale 173.535